Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy
Ischemic stroke is the most common type of stroke and thrombolytic therapy is the only approved treatment. However, current thrombolytic therapy with tissue plasminogen activator (tPA) is often hampered by the increased risk of hemorrhage. Plasmin, a direct fibrinolytic, has a significantly superior...
Guardado en:
Autores principales: | Ramsha Aamir, Cameron Fyffe, Netanel Korin, Daniel A. Lawrence, Enming J. Su, Mathumai Kanapathipillai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e7af1584984b4c5993114a2c6b019efb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting
por: Harry Menon, et al.
Publicado: (2018) -
Nanoformulations of natural products for management of metabolic syndrome
por: Taghipour YD, et al.
Publicado: (2019) -
Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective
por: Davatgaran-Taghipour Y, et al.
Publicado: (2017) -
Effect of heparin on in vitro capacitation of boar sperm
por: DAPINO,DORA G, et al.
Publicado: (2006) -
Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
por: Qi Q, et al.
Publicado: (2017)